Repros Therapeutics Inc. Former Employee Investigation

An analysis on account of above and accepted advisers of Repros Therapeutics, Inc. (Public, NASDAQ: RPRX) apropos abeyant Employee Retirement Income Security Act (“ERISA”) Breach of Fiduciary Duty was announced.

Those who are above or accepted advisers or are a affiliate of any of Repros Therapeutics, Inc. investment affairs or accumulation administration retirement affairs and purchased or captivated Repros Therapeutics, Inc. (Public, NASDAQ: RPRX) shares or accept advice apropos to this investigation, you should acquaintance the Shareholders Foundation, Inc. at email: mail(at)shareholdersfoundation.com or alarm us at: +1 (858) 779 - 1554. Repros Therapeutics, Inc. has been accused of balance artifice and according to a an analysis by a law close beneath ERISA advisers (former and current) of Repros Therapeutics, Inc. (Public, NASDAQ: RPRX) may be acceptable to book a ERISA complaint for putting banal options at accident if they can prove their employer abandoned its fiduciary assignment to them. The Fiduciary assignment refers to a company’s albatross to the humans who advance in it and if an employer puts the company’s absorption advanced of the investors’, it has broken its fiduciary duty, so the investigation.

Repros Therapeutics, Inc. faces a balance chic action accusation over declared violations of Federal Securities Laws on account of purchasers of the accepted banal of Repros Therapeutics, Inc. (NASDAQ: RPRX) accepted banal from July 1, 2009 through August 3, 2009. An broker filed a proposed balance chic action accusation in the United States District Court for the Southern District of Texas adjoin Repros Therapeutics and others alleging violations of Federal Securities Laws. According to the complaint the plaintiff alleges that Repros Therapeutics and assertive of its admiral abandoned Section 10(b) and 20(a) of the Securities Exchange Act of 1934 by arising amid July 1, 2009 through August 3, 2009 ambiguous statements apropos the adverse contest that patients suffered in analytic trials for Repros Therapeutics advance biologic applicant Proellex. According to a columnist absolution by the law close the complaint alleges that if Repros Therapeutics appear the accuracy apropos the calmness of the adverse events, its banal amount dropped, damaging investors. On August 3, 2009 Repros Therapeutics appear that it was suspending all added dosing of Proellex in their analytic trials as a aftereffect of austere adverse events. The August 3rd advertisement appear that the adverse contest were added common and added austere than Repros Therapeutics had ahead reported, so the investigation. As a aftereffect of this news, Repros Therapeutics 's banal (NASDAQ: RPRX) fell over 70%. Repros Therapeutics Inc., amid in The Woodlands, Texas, is a development-stage biopharmaceutical aggregation focused on the development of articulate baby atom drugs for unmet medical needs. Repros Therapeutics arch drug, Proellex, is a careful acquaintance of the progesterone receptor and is accepting developed for the analysis of uterine fibroids, anemia associated with boundless menstrual bleeding apropos to uterine fibroids, or anemia associated with uterine fibroids and endometriosis. Repros Therapeutics Inc. (NASDAQ: RPRX) appear in 2007 Total Revenue of $1.51million and in 2008 Total Revenue of $0.43million. Shares of Repros Therapeutics Inc. (NASDAQ: RPRX) traded afresh at $1.27 per share, down from a 52weekHigh of $13.94 per allotment and $14.56 per allotment in 2007.